OnKure Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OKUR research report →
Range $14 – $14
Price Chart
About the company
OnKure, Inc. , established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases.
- CEO
- Nicholas A. Saccomano
- IPO
- 2021
- Employees
- 45
- HQ
- Boulder, CO, US
Get TickerSpark's AI analysis on OKUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $102.82M
- P/E
- -0.73
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 0.74
- EV/EBITDA
- 1.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -49.02%
- ROIC
- -35.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-830,000+0.0%
- Op Income
- $-62,950,000
- Net Income
- $-59,517,000-13.0%
- EPS
- $-4.40-11.4%
- OCF Growth
- -1.4%
- FCF Growth
- -1.4%
- 52W High
- $5.38
- 52W Low
- $2.23
- 50D MA
- $3.52
- 200D MA
- $3.66
- Beta
- 0.30
- RSI (14)
- 28
- Avg Volume
- 211.53K
No earnings-call transcripts are available for OKUR yet.
- Free Float
- 72.2%
- Shares Outstanding
- 40.50M
- Float Shares
- 29.23M
of shares held by institutions
51 13F filers
Buy/sell ratio 1.92. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 4.00M | 0 |
| Bvf Inc/Il | 3.24M | ▲ 1.26M |
| Acorn Capital Advisors, LLC | 2.84M | 0 |
| Stepstone Group LP | 2.66M | 0 |
| Adar1 Capital Management, LLC | 2.24M | ▼ 196.26K |
| Vivo Capital, LLC | 1.93M | 0 |
| Vestal Point Capital, LP | 1.83M | ▼ 14.12K |
| Blackrock, Inc. | 1.50M | ▲ 1.45M |
| Trails Edge Capital Partners, LP | 1.44M | ▲ 1.44M |
| Vanguard Capital Management LLC | 1.44M | ▲ 854.56K |
| Adage Capital Partners Gp, L.L.C. | 1.20M | 0 |
| Citadel Advisors LLC | 1.19M | ▲ 1.15M |
Held by 80 ETFs
Biggest fund positions in OKUR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 21, 26 | Saccomano Nicholas A | sell | 87 |
| Sep 21, 26 | Leverone Jason A. | sell | 302 |
| Aug 7, 26 | Manke Isaac | other | 0 |
| Aug 7, 26 | Mathers Edward T | other | 22,350 |
| Aug 7, 26 | Ratcliffe Liam | other | 22,350 |
| Aug 7, 26 | Phillips Andrew John | other | 22,350 |
| Aug 7, 26 | Manke Isaac | other | 300,000 |
| Aug 7, 26 | Manke Isaac | other | 15,300 |
| Aug 7, 26 | Manke Isaac | sell | 15,300 |
| Aug 7, 26 | Jansen Valerie Malyvanh | other | 22,350 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OKUR coverage
Recent articles, reports, and earnings notes.
No research on OKUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OKUR report →OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
globenewswire.com · Aug 31
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
globenewswire.com · Aug 4
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
marketbeat.com · Jul 15
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
globenewswire.com · Jul 2
OnKure Therapeutics Reports First Quarter 2026 Financial Results
globenewswire.com · May 5
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
globenewswire.com · Mar 27
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com · Mar 12
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Given Consensus Rating of “Hold” by Analysts
defenseworld.net · Feb 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.